{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:30:33Z","timestamp":1780540233374,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,11]]},"DOI":"10.7759\/cureus.92087","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:50:31Z","timestamp":1757631031000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparative Effectiveness and Safety of Intravenous Versus Oral Iron Therapy With Iron-Deficient Heart Failure: A Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Parag N","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devang","family":"Mangal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival","volume":"58","author":"Okonko DO","year":"2011","unstructured":"Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011, 58:1241-51. 10.1016\/j.jacc.2011.04.040","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker SD","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009, 361:2436-48. 10.1056\/NEJMoa0908355","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020","volume":"36","author":"Ponikowski P","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al.. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency\u2020. Eur Heart J. 2015, 36:657-68. 10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomized controlled trial","volume":"396","author":"Ponikowski P","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, et al.. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomized controlled trial. Lancet. 2020, 396:1895-904. 10.1016\/S0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra PR","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC, et al.. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. The Lancet Journal. 2022, 400:2199-299. 10.1016\/S0140-6736(22)02083-9","journal-title":"The Lancet Journal"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT-HF randomized clinical trial","volume":"317","author":"Lewis GD","year":"2017","unstructured":"Lewis GD, Malhotra R, Hernandez AF, et al.. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT-HF randomized clinical trial. JAMA. 2017, 317:1958-66. 10.1001\/jama.2017.5427","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106345","article-title":"Comparative efficacy of intravenous and oral iron supplements for the treatment of iron deficiency in patients with heart failure: a network meta-analysis of randomized controlled trials","volume":"182","author":"Mei Z","year":"2022","unstructured":"Mei Z, Chen J, Luo S, Jin L, Liu Q, Chen Y. Comparative efficacy of intravenous and oral iron supplements for the treatment of iron deficiency in patients with heart failure: a network meta-analysis of randomized controlled trials. Pharmacol Res. 2022, 182:106345. 10.1016\/j.phrs.2022.106345","journal-title":"Pharmacol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2021.1703","article-title":"Indirect comparison between ferric carboxymaltose and oral iron replacement in heart failure with reduced ejection fraction: a network meta-analysis","volume":"91","author":"Sciatti E","year":"2021","unstructured":"Sciatti E, Nesti U, Di Lenarda A. Indirect comparison between ferric carboxymaltose and oral iron replacement in heart failure with reduced ejection fraction: a network meta-analysis. Monaldi Arch Chest Dis. 2021, 91:332-7. 10.4081\/monaldi.2021.1703","journal-title":"Monaldi Arch Chest Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko DO","year":"2008","unstructured":"Okonko DO, Grzeslo A, Witkowski T, et al.. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008, 51:103-12. 10.1016\/j.jacc.2007.09.036","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen DJ","year":"2017","unstructured":"van Veldhuisen DJ, Ponikowski P, van der Meer P, et al.. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017, 136:1374-83. 10.1161\/CIRCULATIONAHA.117.027497","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz RJ","year":"2023","unstructured":"Mentz RJ, Garg J, Rockhold FW, et al.. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med. 2023, 389:975-86. 10.1056\/NEJMoa2304968","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia","volume":"168","author":"Beck-da-Silva L","year":"2013","unstructured":"Beck-da-Silva L, Piardi D, Soder S, et al.. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013, 168:3439-42. 10.1016\/j.ijcard.2013.04.181","journal-title":"Int J Cardiol"},{"key":"ref14","article-title":"The effects of ferrous sulfate supplementation on left ventricular intrinsic function by global longitudinal strain in systolic heart failure patient with iron deficiency anaemia","volume":"55","author":"Sagita RS","year":"2017","unstructured":"Sagita RS, Suryani LD, Siswanto BB, et al.. The effects of ferrous sulfate supplementation on left ventricular intrinsic function by global longitudinal strain in systolic heart failure patient with iron deficiency anaemia. Eur J Heart Fail. 2017, 55:360-4.","journal-title":"Eur J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519847352","article-title":"Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure","volume":"47","author":"Zdravkovic SC","year":"2019","unstructured":"Zdravkovic SC, Nagorni SP, Cojbasic I, et al.. Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure. J Int Med Res. 2019, 47:3179-89. 10.1177\/0300060519847352","journal-title":"J Int Med Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1151","article-title":"Oral ferrous sulphate improves functional capacity on heart failure patients with iron deficiency anemia","volume":"17","author":"Suryani LD","year":"2022","unstructured":"Suryani LD, Raharjo SB, Sagita R, et al.. Oral ferrous sulphate improves functional capacity on heart failure patients with iron deficiency anemia. Glob Heart. 2022, 17:81. 10.5334\/gh.1151","journal-title":"Glob Heart"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2092","article-title":"Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study","volume":"23","author":"Karavidas A","year":"2021","unstructured":"Karavidas A, Troganis E, Lazaros G, et al.. Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study. Eur J Heart Fail. 2021, 23:593-7. 10.1002\/ejhf.2092","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan MA","year":"2014","unstructured":"Puhan MA, Sch\u00fcnemann HJ, Murad MH, et al.. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014, 349:g5630. 10.1136\/bmj.g5630","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-023-00611-3","article-title":"Pathophysiology and treatment opportunities of iron deficiency in heart failure: is there a need for further trials?","volume":"20","author":"Tkaczyszyn M","year":"2023","unstructured":"Tkaczyszyn M, Fudim M, Ponikowski P, Biegus J. Pathophysiology and treatment opportunities of iron deficiency in heart failure: is there a need for further trials?. Curr Heart Fail Rep. 2023, 20:300-7. 10.1007\/s11897-023-00611-3","journal-title":"Curr Heart Fail Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/401945-comparative-effectiveness-and-safety-of-intravenous-versus-oral-iron-therapy-with-iron-deficient-heart-failure-a-network-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:50:32Z","timestamp":1757631032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/401945-comparative-effectiveness-and-safety-of-intravenous-versus-oral-iron-therapy-with-iron-deficient-heart-failure-a-network-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.92087","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}